“…Different human melanoma antigens should be considered as determinants in antitumour response – among others, non‐specific proteins (MAGE 1, MAGE 3, BAGE, GAGE), specific melanosomal proteins (MART‐1, GP100, tyrosinase, TRP‐1), specific mutated proteins (beta‐catenin, MUM‐1 and CD‐4) and carbohydrate epitopes (GM2, GD2, 9–0‐acetyl GD3) 3,4 . Regression seems to represent the ultimate immunological reaction aimed at tumour antigenic complexes but does not exclude further extension of the disease, as illustrated by patients with metastatic melanoma of undetermined origin 5–8 …”